The purpose of this study is to determine if a non-invasive cancer treatment, high-dose stereotactic body radiotherapy (SBRT), is associated with changes in circulating tumor cells counts in patients with low- and intermediate-risk prostate cancer.
SBRT (stereotactic body radiotherapy) may decrease or actually increase CTC levels in patients with cancer, and knowledge about the effects of different therapies, including SBRT, on CTC levels will be of general interest to the oncology community. Patients will undergo blood draws at defined times as indicated below. 1. Prior to CT-simulation, but more than 2 days after digital rectal examination 2. Within 24 hours following CT simulation (an endorectal balloon is used at the time of simulation) 3. Within 24 hours following the first treatment 4. Within 24 hours following the third treatment 5. Within 1 week following the fifth treatment
Study Type
OBSERVATIONAL
Enrollment
2
Blood Drawing to measure circulating tumor cells counts.
University of Texas Southwestern Medical Center
Dallas, Texas, United States
To review the level of changes in circulating tumor cells with radiation.
The investigator will review the coutns of circulating tumor cells (CTC). If there are significant changes in CTC levels with radiation, future studies will determine the prognostic significance of this information.
Time frame: 2 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.